Decoy Therapeutics (DE:FP11)
FRANKFURT:FP11
FP11 Stock Chart & Stats
€5.23
--
Market closed
€5.23
--
Day’s Range― - ―
52-Week Range€4.13 - €673.92
Previous CloseN/A
VolumeN/A
Average Volume (3M)205.00
Market Cap
€2.88M
Enterprise Value-€3.08M
Total Cash (Recent Filing)€7.82M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume95
30 Day Avg. Volume205
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage (no Debt)Having no recorded debt materially reduces fixed financial obligations and bankruptcy risk, giving management flexibility to fund R&D through equity or partnerships. Over a multi-month horizon this preserves optionality for non-dilutive financing and strategic moves without debt covenants.
Regained Nasdaq Compliance Via Reverse SplitRestoring compliance secures the company’s listing and preserves access to public capital markets and institutional investors. That structural change reduces immediate delisting overhang and supports the firm’s ability to raise equity or engage investors over the next several quarters.
Improving Free Cash Flow Trend (TTM)A meaningful positive change in FCF growth signals improving cash efficiency in operations, even if absolute FCF is negative. Sustained improvement can extend runway, reduce near-term dilution needs, and indicates management progress in cost or program prioritization.
Bears Say
Pre-revenue With Sustained Net LossesBeing pre-revenue and repeatedly loss-making means the business lacks commercial cash inflows and depends on external financing. Over 2-6 months, this creates structural funding risk and uncertainty around the timing and scale of any future revenue realization or commercial viability.
Ongoing Cash Burn And Negative Operating Cash FlowSustained negative operating cash flow indicates the company is consuming cash to fund operations and R&D. Without revenue, continued burn forces dilution or financing, compresses runway, and limits ability to sustain multi-stage clinical programs without recurrent capital raises.
Eroding Shareholders' Equity / Weakened Balance SheetA shrinking equity base reduces the balance-sheet cushion for absorbing losses and constrains borrowing or partnership leverage. Over months this deterioration increases vulnerability to funding shocks and limits options for non-dilutive financings or strategic investments.
Decoy Therapeutics News
FP11 FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was €4.13 and its highest was €673.92 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is €2.88M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Currently, no data Available
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DE:FP11
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―
Options Prices
Currently, No data available
---